This study is testing a new treatment called metreleptin for people with Partial Lipodystrophy (PL), a condition where the body doesn't store fat properly. It's a Phase III trial, which means it's in the final stages of testing in people. The study is "double-blind," meaning neither the participants nor the researchers know who is getting the real treatment or a placebo, which is a fake treatment. Metreleptin is given daily through a small injection under the skin, known as subcutaneous (SC) injection.

To join, you need to have Familial Partial Lipodystrophy (FPLD) and problems controlling your metabolism, like high blood sugar levels (HbA1c ≥7%) or very high triglycerides (TGs ≥500 mg/dL). You must also be on a stable treatment plan. However, you cannot join if you've used metreleptin before, have high leptin levels, or have lipodystrophy from other causes like radiation.

• The study examines safety and effectiveness of metreleptin.
• Participants cannot have used metreleptin before.
• Other specific health conditions may prevent participation.